Citigroup Begins Coverage on AstraZeneca (LON:AZN)

Analysts at Citigroup initiated coverage on shares of AstraZeneca (LON:AZN) in a report released on Tuesday, Marketbeat reports. The firm set a “buy” rating and a £170 price target on the biopharmaceutical company’s stock. Citigroup’s price target points to a potential upside of 25.85% from the stock’s current price.

Other research analysts have also recently issued reports about the stock. Shore Capital reiterated a “buy” rating on shares of AstraZeneca in a report on Friday, January 16th. JPMorgan Chase & Co. reaffirmed an “overweight” rating on shares of AstraZeneca in a research report on Thursday, January 15th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of AstraZeneca from £105 to £110 and gave the company a “sell” rating in a research note on Thursday, January 15th. Berenberg Bank boosted their price objective on shares of AstraZeneca from £142 to £145 and gave the stock a “buy” rating in a research note on Tuesday, October 21st. Finally, Jefferies Financial Group restated a “buy” rating and set a £150 target price on shares of AstraZeneca in a report on Monday, November 10th. Five investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of £145.83.

AstraZeneca Trading Down 2.7%

Shares of LON AZN opened at £135.08 on Tuesday. AstraZeneca has a twelve month low of GBX 9,573.51 and a twelve month high of £144.10. The firm has a market cap of £209.41 billion, a PE ratio of 22.44, a price-to-earnings-growth ratio of 0.86 and a beta of 0.17. The business has a fifty day simple moving average of £137.66 and a two-hundred day simple moving average of £125.59. The company has a quick ratio of 0.59, a current ratio of 0.93 and a debt-to-equity ratio of 73.83.

Insider Buying and Selling

In other AstraZeneca news, insider Nazneen Rahman sold 297 shares of the firm’s stock in a transaction that occurred on Thursday, December 18th. The shares were sold at an average price of £134.96, for a total value of £40,083.12. 0.14% of the stock is owned by insiders.

About AstraZeneca

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas – Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology.
Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.